



# *References*




---

## References


- **Alamanos Y., Voulgari P.V. and Drosos A.A. (2006):** Incidence and prevalence of rheumatoid, based on 1987 American college of rheumatology criteria: a systematic review. *Semin Arthritis Rheum*, 36(3): 182-8.
- **Alenius G.M., Berglin E. and Rantappa Dahlqvist S. (2006):** Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. *Ann Rheum Dis*; 65(3): 398-400.
- **Aletaha D., Funovits J., Breedveld F.C., Sharp J., Segurado O. and Smolen J.S. (2009):** Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. *Arthritis Rheum*; 60: 1242-9.
- **Aletaha D., Neogi T., Silman A.J. et al. (2010):** Rheumatoid arthritis classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative. *Arthritis Rheum*. Sept; 62(9): 2569-81.
- **Aletaha D., Ward M.M., Machold K.P., Nell V.P., Stamm T. and Smolen J.S. (2005):** Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. *Arthritis Rheum*; 52: 2625-36.




- 
- **Alvarez-Lafuente R., Fevnainedez-Guitie'rrez B., de Migval S. et al. (2005):** Pottential relation shipbetween her pesuiruses and rheumatoid arthritis: analysis with quantitativereel tie polymerase chain reaction. *Ann Rheum-Dis.* 64(9): 1357-9.
  - **Arnett F., Edworthy S., Bloch D., Mc Shane D., Fries J., Cooper N. et al. (1988):** The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 31(3): 315-24.
  - **Aubry M.C., Maradit-Kremers H., Reinalda M.S., Crowson C.S., Edward W.D. and Gabriel S.E. (2007):** Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis *J Rheumatol*; 34: 937-342.
  - **Avalos I., Rho Y.H., Chung C.P. et al. (2008):** Atherosclerosis in rheumatoid arthritis. *Clin Exp Rheumatol*, 26(Suppl 51): S5-S13.
  - **Bacon P.A. (1993):** Rheumatoid arthritis. In *Mc Cary DJ. Koopman WJ: Arthritis and allied conditions*, 12<sup>th</sup> ed. Philadelphia. Lea and Febiger; 811-840.
  - **Bagnato G., De Filippis L.G., Caliri A. et al. (2006):** Comparison of levels of anxiety and depression in patients with autoimmune and chronic-degenerative rheumatic: preliminary data. *Rheumatismo*, 58(3): 206-11.
  - **Balandrud N., Roudier J. and Roudier C. (2004):** Epstein-Barr virus and rheumatoid arthritis. *Auto immune Rev*; 3(5): 362-7.




- 
- **Banal F., Dougados M., Combesure C. and Gossec L. (2009):** Sensitivity and specificity of the American college of rheumatology 1987 criteria for the diagnosis of rheumatoid arthritis according to disease duration: a systematic literature review and meta-analysis. *Ann Rheum Dis*; 68(7): 1184-91.
  - **Bang E., Egerer K., Gaudiard A. et al. (2007):** Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. *Arthritis Rheum*; 56: 2503-11.
  - **Bartlett S.J., Piedmont R., Bilderback A. et al. (2003):** Spiritually, well-being, and quality of life in people with rheumatoid arthritis. *Arthritis Rheum*, 49: 778-783.
  - **Bazzichi L., Maser J., Piccini A., Rucci P., Del Debbio A. et al. (2005):** Quality of life in rheumatoid arthritis: Impact of disability and life time depressive spectrum Symptomatology. *Clin Exp Rheumatol*. 23(6): 783-788.
  - **Bennett J.C. (1988):** Clinical features. In primer on the rheumatic diseases, edited by Ralph H, Scheumacher M and John H Klippel. 9<sup>th</sup> ed; 88-92.
  - **Bettelli E., Carrier Y. and Gao W. (2006):** Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. *Nature*; 441: 235-238.
  - **Binstadt B.A., Patel P.R. and Alencar H. (2006):** Particularities of the vasculature can promote the organ specificity of autoimmune attack. *Nat Immunol*; 7(3): 284-292.




- 
- **Bizzara N., Tonutti E., Tozzoli R. and Villatta D. (2007):** Analytical and diagnostic characteristics of 11 2<sup>nd</sup> and 3<sup>rd</sup> generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. *Clin Chem*; 53: 1527-33.
  - **Boers M., Brooks P., Simon L.S., Strand V. and Tugwell P. (2005):** OMERACT: an international initiative to improve outcome measurement in rheumatology. *Clin Exp Rheumatol*; 23 (5 Suppl 39): S10-S13.
  - **Botega N.J. and Dalgalarondo P. do Paciente (2002):** In: Botega N.J. *Pratica Psiquiatrica no hospital geral: Interconsulta with emergencia*. 2<sup>nd</sup> ed. Port Alegre: Artmed, 155-82.
  - **Bottini N., Vang T., Cucca F. and Mustelin T. (2006):** Role of PTPN22 in type 1 diabetes and other autotimmune disease. *Semin Immunol*; 18: 207-213.
  - **Brennan F.M., Chantry D., Jackson A., Maini R. and Feldmann M. (1989):** Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. *Lancet*; 2: 244-247.
  - **Brooks P., Boers M., Simon L., Strod V. and Tugwell P. (2007):** Outcome measures in rheumatoid arthritis-the OMERACT Process. *Exp. Rev Clin Immunol*; 3: 271-275.
  - **Brown A.K., Conaghan P.G., Karim Z., Quinn M.A., Ikeda K., Peterfy C.G. et al. (2008):** An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. *Arthritis Rheum*; 58: 2958-67.




- 
- **Brown J., Bowling A. and Flynn T.N. (2004):** Model of quality of life. A taxonomy and systematic review of the literature. European Forum on Population Ageing, 64: 293-323.
  - **Brown J., Bowling A. and Flynn T.N. (2004):** Models of quality of life. Taxonomy and systemic review of literature. JAMA, 278: 47-50.
  - **Buhrten B., Gerdes N. and Jackel W.H. (2005):** Development and psychometric testing of a patient questionnaire for medical rehabilitation (IRES-3). Rehabilitation (Stuttg); 44: 63-74.
  - **Burton W., Marrison A., Maclean R. et al. (2006):** Systemic review studies of productivity loss due to rheumatoid arthritis. Occup Med, 56: 18-27.
  - **Calpan A. (1993):** Certain unusual radiological appearances in the chest coal mires suffering from rheumatoid arthritis. Thorax; 8: 29-37.
  - **Caponi L., Petit-Teixeire E., Sebbag M., Bongiorno F., Moscato S. et al. (2005):** A family based study shows no association between rheumatoid arthritis and the PAD14 gene in a white French population. Ann rheum Dis; 64: 587-593.
  - **Carr A.J. and Higginson J. (2001):** Are quality of life measures patients centred? BMJ; 322: 1357-60.
  - **Cault S.J. and spyker J.M. (1994):** Beneficial effect of immobilization of joint in rheumatoid arthritis. Arthritis Rheum; 91: 34-44.




- 
- **Cella D., Wagner L., Cashy J., Hensing T.A., Yount S. and Lilenbaum R.C. (2007):** Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment cancer therapy. *J Natl Cancer Inst Monogr*; 37: 53-60.
  - **Cella D.F. and Bonomi A.E. (1995):** Measuring quality of life: 1995 update. *Oncology (Williston Park)*; 9(Suppl): 47-60.
  - **Cereda E., Turrini M., Ciapanna D et al. (2007):** Assessing energy expenditure in cancer patients: a pilot validation of a new wearable device. *JPEN J Parenter Enteral Nutr*, 31: 502-507.
  - **Cesari M., Kritchvsky S.B., Newman A.B. et al. (2009):** Added value of physical performance measures in predicting adverse health-related events: results from the health, aging and body composition study. *J Am Geriatr Soc*, 57: 251-259.
  - **Chakravarty K., McDonald H., Pullar T. et al. (2008):** BSR/BHPR guideline for disease-modifying anti-rheumatic drugs (DMARD) therapy in consultation with the British Association of Dermatologists. *Rheumatology*, 47(6): 924-25.
  - **Chang M., Rowland C.M., Garcia V.E., Schrodi S.J., Catanese J.J., Van der Helm-Van Mil A.H. et al. (2008):** A large-scale rheumatoid arthritis genetic study identifies association at chromosome 9q33.2. *Plos Genet* ; 4: e1000107.
  - **Chiou C.F., Cherbourne C.D., Cornelio I., Lubeck D.P. et al. (2006):** Revalidation of the original cedars-Sinai Health Related Quality of life in rheumatoid Arthritis (CSHQ-RA) short form instrument. *J Rheum*; 33: 256-62.




- 
- **Chiou C.F., Sherbourne C.D., Ofman J., Lee M., Lubeck D.P. et al. (2004):** Development and validation of cedars-Sinai-Health Related Quality of life in Rheumatoid Arthritis (CSHQ-RA) short form instrument. *Arthritis Rheum*; 51: 358-64.
  - **Cleeland C.S. (2007):** Symptom burden multiple symptoms and their impact as patient-reported outcomes. *J Natl Cancer Inst Monogr*; 37: 16-21.
  - **Cohen G., Gossec L., Dougados M., Cantagrel L.A., Goupille P., Daures T.P. et al. (2007):** Radiological damage in patients with rheumatoid arthritis on sustained remission. *Ann Rheum Dis*; 66:358-63.
  - **Cohen S.B. et al. (2006):** Rituximab for rheumatoid arthritis refractory to anti-TNF therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. *Arthritis Rheum*; 54: 2793-3806.
  - **Combe B., benessiano J., Berenbaum F. et al. (2007):** The ESPOIR cohort: a ten-year follow-up of early arthritis in france: methodology and baseline characteristics of the 813 included patients. *Joint Bone Spine*, 74: 440-5.
  - **Condemi J., Barnett E.V. and Atwater E.C. (1995):** The significance of antinuclear factors in rheumatoid arthritis. *Arth. Rheum*; 8: 1080.
  - **Cuthbert R.J. and Ludlum C.A. (1999):** Haematological changes in systemic disease. In: *clinical haematology* edited by Christopher A.L., Churchill Living Stone. New York, London, Melbourne, Tokyo. Chap 29. 301.




- 
- **Damon W., Menon J. and Cotton Bronk K. (2003):** The development of purpose during adolescence. *Appl Dev Sci*, 7: 119-128.
  - **Davis J.M., Crowson C.S., Maradil-Kremers H., Therneau T.M., Roger V.L. and Gabriel S.E. (2006):** Mortality following heart failure is higher among rheumatoid arthritis (RA) subjects compared to non-Ra subjects. *Arthritis a Rheumatism*; 54(9): S387.
  - **Davis J.M., Roger V., Crowson C.S. and Maradit Kremers H. (2007):** Management and treatment of heart failure among rheumatoid arthritis subjects compared to non-RA subjects. *Arthritis Rheum*; 56(9): S415.
  - **de Groot K. (2007):** Renal manifestations in rheumatic diseases. *Internist (berl)*; 48(8): 779-85.
  - **Decker J.L., Malone D.G. and Wilder R.L. (1994):** Rheumatoid arthritis. *Ann Intern Med*; 101: 810.
  - **del Rincón I., O'leary D.H., Freeman G.L. and Escalante A. (2007):** Acceleration of atherosclerosis during the course of rheumatoid arthritis. *Atherosclerosis*; 195: 354-360.
  - **Diener E. (2000):** Subjective well-being. The science of happiness and a proposal for a national index. *Am Psychol*, 55: 34-43.
  - **Diener E. (2006):** Guidelines for national indicators of subjective well-being and ill-being. 7: 397-404.
  - **Dixon W.G. and Symmons D.P. (2005):** Does early rheumatoid arthritis exist? *Best Pract Res Clin Rheumatd*; 19: 37-53.




- 
- **Dolan P., Peasgood T. and White M. (2005):** Measuring quality of life of the elderly, public economics and quality of life, 282-297.
  - **Dolan P., Peasgood T. and White M. (2005):** Review of research on the influences on personal well being and application to policy making. Soc. Indic Res, 64: 293-323.
  - **Dörner T., Egerer K., Feist E. and Burmester G.R. (2004):** Rheumatoid factor revisited. Curr Opin Rheumatol; 16: 246-53.
  - **Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J. and Stoddart G.L. (2005):** Cost-benefit analysis. Methods for the Economic evaluation of health care programmes. Oxford. England: Oxford medical Publications; 211-245.
  - **Edmonds P.J. (1997):** Radiological findings in rheumatoid arthritis. Clinical Rheumatology; 52: 95.
  - **Ellegard K., Torp-Pedersen S., Terslev L. et al. (2009):** Ultrasound colour Doppler measurements in a single joint as measure of disease activity in patients with rheumatoid arthritis- assessment of current validity. Rheumatology, 48: 254-257.
  - **Emery P. (1994):** The roche rheumatology prize lecture the optimal management of early rheumatoid disease: the Key of preventing disability. Br J Rheumatol; 33: 765-768.
  - **Emery P. et al. (2008):** IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biologicals: results from a 24-week multicentre randomized placebo-controlled trial. Ann Rheum Dis; 67: 1516-1523.




- 
- **Emery P. et al., (2008):** Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. *Lancet*; 372: 375-382.
  - **Erikson R. (1993):** Descriptions of inequality: the swedish approach to welfare research. In Nussbaum M, Sen A (eds) *the Quality of life*. Oxford, 67-83.
  - **Farr M., Scott D.L., Constabale J.J. et al., (1993):** Thrombocytosis of active rheumatoid disease. *Ann Rheum. Dis*; 42: 545-549.
  - **Felson D.T., Anderson J.J., Boers M. et al. (1995):** American College of Rheumatology. Preliminary definitio0n of improvement in rheumatoid arthritis. *Arthritis Rheum*; 38: 727-735.
  - **Fernando M.M., Stevens C.R., Walsh E.C., De Jager P.L., Goyette P., Plenge R.M., Vyse T.J. and Rioux J.D. (2008):** Defining the role of the MHC in auto immunity: a review and pooled analysis. *Plos Genet*; 4: e1000024.
  - **Ferrans C., Zerwic J., Wilbur J. and Larson J. (2005):** Conceptual model of helath-related quality of life. *J Nurs Scholarsh*; 37: 336-42.
  - **Ferrans C.E. (2007):** Differences in what quality of life instruments measure. *J. Natl Cancer Inst Monogr*; 37: 22-6.
  - **Firestein G.S. (2004):** Rheumatoid Arthritis. *ACP medicine medicina. Arthritis Rheam*; 1547-1659.




- 
- **Frenandes L., Sullivan S., Mcforlane J.C. et al. (1999):** Studies on the frequency and pathogenesis of liver involvement in rheumatoid arthritis. *Ann Rheum Dis*; 38: 501-6.
  - **Fries I.F., Spitz P., Kraines R.G. and Holman H.R. (1980):** Measurement of patient outcome in arthritis. *Arthritis Rheum*; 23: 137-145.
  - **Fries J., Spitz P.W. and Young D.Y. (1982):** The dimensions of health outcomes: The health assessment questionnaire, disability and pain scales. *J Rheumatol*; 9: 789-93.
  - **Froberg D.G. and Kane R.L. (1989):** Methodology for measuring health. State preference. II: Scaling methods. *J Clin Epidemiol*; 42: 459-471.
  - **Gabriel S.E. (2010):** Heart disease and rheumatoid arthritis: understanding the risks. *Ann Rheum Dis*, 69(Suppl 1): 61-64.
  - **Gafni A. and Birch S. (1995):** Preferences for outcomes in economic evaluation: an economic approach to addressing economic problems. *Soc Sci Med*; 40: 767-776.
  - **Genoves M.C. et al. (2005):** Abatacept for rheumatoid arthritis refractory to tumour necrosis factor alpha inhibition. *N Engl J Med*; 353-114-1123.
  - **Geuskens G.A. Hazes J.M., Barendregt P.J., Burdorf A. (2008):** Work and sick leave among patients with early inflammatory joint conditions. *Arthritis Rheum*, 59: 1458-1466.




- 
- **Geuskens G.A., Hazes J.M., Barendregt P.J. et al. (2008):** Predictors of sick leave and reduced productivity at work among persons with early inflammatory joint conditions. *Scand J Work Environ Health*, 34: 420-429.
  - **Golding D.N. (1989):** Rheumatoid arthritis in "A synopsis of rheumatic disease". 5<sup>th</sup> ed., Wright, London; 51-88.
  - **Gordon D.A. and Hastings D.E. (2003):** Clinical features of rheumatoid arthritis in: Hochberg MC, Silman AJ, smolen JF et al., eds. *Rheumatology*. 3<sup>rd</sup>. ed. New York, NY: Mosby; 765: 780.
  - **Gregersen P.K. (2005):** Pathways to gene identification in rheumatoid arthritis: PTPN22 and beyond. *Immunol Rev*; 204: 74-86.
  - **Hardwicke J. and Squire J.R. (1992):** The basis of the erythrocyte sedimentation rate. *Clin. Sci*; 2: 333.
  - **Harris E.D. (2001):** Clinical feature of rheumatoid arthritis. In Kelly, W.N., Harris E.D., Ruddy S. and Sledge C.B.: *A text book of rheumatology*, 5<sup>th</sup> edition, vol., 2. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo, W.B. Saunders Company; 967-1010.
  - **Harris E.D., Kelly W.N., Ruddy S. and Sledge C.B. (2001):** Clinical features of rheumatoid arthritis 6<sup>th</sup> edition. W.B. Saunders Company, Philadelphia, Chap. 65: 467-1000.




- 
- **Hasform I., Albertsson K., Boonen A., Van der Heijde D.M., Landowe R. and Svensson B. (2009):** Remission achieved after 2 years treatment with low dose prednisolone in addition to DMARDs in early RA is associated with reduced joint destruction still present after 4 years: an open two year continuation study. *Ann Rheum Dis*; 68: 508-13.
  - **Hoghund M. and Tordai P. (1996):** Ultrasound imaging of the wrist and hand. 479-498.
  - **Huizinga T.W., Amos C.L., Van der Helm-Van Mil A.H., Chen W., Van Gaalen F.A. et al. (2005):** Refine the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. *Arthritis Rheum*; 52: 3433-3438.
  - **Ikari K., Momohara S., Inoue E., Tomatsu T., Hara M., Yamanaka H. and Kamatani N. (2006):** Haplotype analysis revealed no association between the PTPN22 gene and RA in a Japanese population. *Rheumatology (Oxford)*; 45: 1345-1348.
  - **Iwamoto T., Ikari K., Nakamura T., Kuwahara M., Toyama Y. et al. (2006):** Association between PAD14 and rheumatoid arthritis: a meta-analysis. *Rheumatology (Oxford)*; 45: 804-807.
  - **Kahl K.G., Bens S., Ziegler K., Rudolf S. et al. (2006):** Pro-inflammatory cytokines in patients with current major depressive disorder comorbid with borderline personality disorder. *Biol Psychiatry*, 59(7): 667-71.




- 
- **Kallberg H., Padyukov L. and Plenge R.M. (2007):** Gene-gene and gene environment interacting involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. *Am J Hum Genet*; 80: 867-875.
  - **Kalreskog L., Padyukov L., Lorentzen J. and Alfredsson L. (2006):** Mechanisms of diseases: Genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. *Nat Clin Pract Rheumatol*; 2(8): 425-33.
  - **Kang C.P., lee H.S., Ju H., Cho H., Kang C. and Bae S.C. (2006):** A functional haplotype of the PAD14 gene associated with increased rheumatoid arthritis susceptibility in Koreans. *Arthritis Rheum*; 54: 90-96.
  - **Kang Y.M., Zhang X. and Wagner U.G. (2002):** CD8T cells are required for the formation of ectopic germinal centers. In rheumatoid synovitis. *J Exp Med*; 195: 1325-1336.
  - **Kapitany A., Szabo Z., Lakos G., Aleksza M., Vegari A., Soos L. et al. (2008):** Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in Hungarian patients with rheumatoid arthritis. *Isr Med Assoc J*; 10(1): 32-6.
  - **Keystove E. et al. (2007):** Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. *Arthritis Rheum*; 56; 3896-3908.
  - **Khanna D. (2006):** Health related quality of life: a primer with a focus on scleroderma. *Scleroderma Care Res*; 3: 3-13.




- 
- **King J.T., Tsevat J., Mossay J.J. and Roberts M.S. (2004):** Preference-based quality of life measurement in patients with cervical spondylotic myelopathy. *Spine*; 29: 1271-1280.
  - **Kinloch A., Tatzler V., Wait R. et al. (2005):** Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. *Arthritis Res Ther*; 7: R1421-9.
  - **Klareskog L., Widhe M., Hermansson M. and Ronnelid J. (2008):** Antibodies to citrullinated proteins in arthritis: Pathology and promise. *Curr Opin Rheumatol*; 20(3): 300-5.
  - **Klippel J.H. (1997):** Treatment of rheumatoid arthritis in primer on the rheumatic disease Ed. By Klippel J.H., Wey CN, Wort Mayn RL 11 Ed., Arthritis Foundation, Atlanta, GA; 93.
  - **Knevel R., Schoels M., Husizinga T.W. et al. (2010):** Current evidence for a strategic approach to the management of rheumatoid disease with disease-modifying anti rheumatic drugs: a systematic literature review suforming the EULAR recommendations for the management of rheumatoid arthritis. *Ann Rheum Dis*, 69: 987-94.
  - **Kosinski M., Zhao S.Z., Dedhiya S., Osterhaus J.T. and Ware E. (2000):** Determining minimally important changes in generic and disease. Specific-health related quality of life questionnaire in clinical trials of rheumatoid arthritis. *Arthritis Rheum*; 43: 1478-1487.
  - **Kual M.P. (1994):** Superficial heat and cold. How to maximize benefits. *Phys. Sports Med*; 22(12): 66-74.




- 
- **Kubassova O., Boesen M., Boyele R.D., Cimmino M.A., Jensen K.E. et al. (2007):** Fast and robust analysis of dynamic contrast enhanced MRI data sets. In Proceedings of International Conferences on Medical Image Computing and Computer Assisted intervention; 2: 261-69.
  - **Kuyken W. and Group T.W. (1995):** The world health organization quality of life assessment (WHOQOL): position paper from the world Health Organization. Soc Sci med; 41: 1403-9.
  - **Lee D.M., Kiener H.R., Agarwal S.K., Noss E.H., Watts G.F., Chisaka O. et al. (2007):** Cadherin-11 in synovial lining formation and pathology in arthritis. Science, 315: 1006-1010.
  - **Lee H.S., Remmers E.F., Le J.M., Kastner D.L., Bae S.C., and Gregersen P.K. (2007):** Association of stat4 with rheumatoid arthritis in the Korean population. Mol Med, 13: 455-460.
  - **Lempp H., Scott D. and Kingsley G. (2006):** The personal impact of rheumatoid arthritis patient identity: a qualitative study. Chronic I; 2: 109-120.
  - **Lequerre T. et al. (2008):** Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic onset juvenile idiopathic arthritis or adult onset still disease preliminary experience in France. Ann Rheum Dis; 67: 302-308.
  - **Li X. and Makarov S.S. (2006):** An essential role of NF-Kappa B in the (tumor-Like) phenotype of arthritic synoviocytes. Pro Natl Acad Sci USA; 130: 17432-17437.




- 
- **Liao K.P., Batra K.L., Chibni K.L. et al. (2008):** Anti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis. *Ann Rheum Dis*; 67(11): 1557-61.
  - **Lieberman M.D. and Eisenberger N.J. (2009):** Pains and pleasures of social life. *Science*, 323: 890-891.
  - **Luqmani R., Hennell S., Estrach C. et al. (2009):** British society for rheumatology and british health professionals in rheumatology guideliues for the management of rheumatoid arthritis (after the first 2 years). *Rheumatology* 48(4): 436-69.
  - **Mac Gregor A.L., Snider H., Rigby A.S., Koskonw M., Kaprio J., Aho K. et al. (2000):** Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. *Arthritis and Rheumatism*; 43: 30-7.
  - **Machold K.P., Stamm T.A., Nell V.P., Pflugbei S., Aletaha D. et al. (2007):** Very recent onset rheumatoid arthritis: Clinical and serological patient characteristic associated with radiographic progression over the first years of disease. *Rheumatology (Oxford)*; 46: 342-9.
  - **Majithia V. and Geraci S.A. (2007):** Rheumatoid arthritis: diagnosis and management. *Am J Med*, 120(11): 936-9.
  - **Makinen H., Kautiainen H., Hannonen P., Mottonen T. et al. (2007):** Sustained remission and reduced radiographic anti-rheumatic drugs in early RA. *J Rheumatol*; 34: 316-21.
  - **Mangell M., Gribbin N., Büch et al. (2002):** Psychological well-being in Rheumatoid Arthritis: Relationship to disease variables and affective disturbance. *Psychother Psychosom*, 71: 112-116.




- 
- **Maradit-Kremers H., Crowson C.S., Nicola P.J. et al. (2005):** Increased unrecognized coronary heart disease based study. *Arthritis Rheum*; 52(2): 402-411.
  - **Maradit-Kremers H., Nicola P.J., Crowson C.S., Ballman K.V. and Gabriel S.E. (2005):** Cardiovascular death in rheumatoid arthritis: A population based study. *Arthritis Rheum Mar*; 52(3): 722-732.
  - **Marcora S.M., Lemmey A.B. and Maddison P.J. (2005):** Can progressive resistance training reverse cachexia in patients with rheumatoid arthritis? Results of a pilot study. *J Rheumatol*, 32(6): 1031-1039.
  - **Markham T., Mullan R. and Golden-Mason L. (2006):** Resolution of endothelial activation and down regulation of Tie 2 receptor in psoriatic skin after infliximab therapy. *J Am Acad Dermatol*; 54: 1003-1012.
  - **Marra C.A., Esdaile J.M., Guh D. et al. (2004):** A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. *Med Care*; 42: 1125-1131.
  - **Martinez A., Valdivia A., Pascua L., Salcedo D., Lamas J.R., Fernandez-Arquero M. et al. (2005):** PAD14 polymorphisms are not associated with rheumatoid arthritis in the Spanish population. *Rheumatology (Oxford)*; 44: 1263-1266.
  - **Mathsson L., Mullazehl M., Wick M.C. et al. (2008):** Antibodies against citrullinated vimentin in rheumatoid arthritis. *Arthritis Rheum*; 58: 36-45.




- 
- **Matteson E.L., Cohen M.D. and Conn D.L. (1997):** Rheumatoid arthritis clinical features and systemic involvement. In text book of rheumatology, edited by Dieppe P.A. and Klippel J.H. 2<sup>nd</sup> edition; 1(5): 401-8.
  - **Mattey D.L., Thonson W., Ollier W.E. et al. (2007):** Association of DRB, Shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen of ears follow up from the early rheumatoid arthritis study. *Arthritis Rheum*; 56: 1408-16.
  - **Mc Dowell I. (2006):** Measuring health: A guide to rating scales and questionnaire. 3<sup>rd</sup> ed. New York, NY; Oxford University; 52: 501-504.
  - **Mc Clelland J., Fail B. and Walker D. (1996):** E.S.R., Hb level, plasma and serum viscosity as measure of disease activity in rheumatoid arthritis. *Br. J. Rheumatol*; 36: 156-8.
  - **Mease P.J. and Antoni C.E. (2005):** Psoriatic arthritis treatment: biological response modifiers. *Ann Rheum Dis*, 64(suppl 2): ii78-82.
  - **Merkesdal S., Ruof J., Schoffski O., Bernitt K. et al. (2001):** Indirect medial costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. *Arthritis Rheum*, 44: 528-534.
  - **Metal T. (1994):** A critical appraisal of the quality of life measurements. *Journal of the American Medical Associations*; 272: 619-631.




- 
- **Metsions G.S., Stavropoulos-Kalinoglou A., Veldhuijzen Van Santen J.J. et al. (2008):** Rheumatoid arthritis, cardiovascular disease and physical exercise: a systematic review. *Rheumatology (Oxford)*, 47(3): 239-248.
  - **Mierau M., Schoels M., Gonda G., Fuchs J., Aletaha D. and Smolen J.S. (2007):** Assessing remission in clinical practice. *Rheumatology (Oxford)*; 46: 975-9.
  - **Miller M.C., manning H.B., Jain A., Troeberg L., Dudhia J., Essex D., Sandison A. et al. (2009):** Membrane type 1 matrix metalloproteinase is a crucial promoter of synovial invasion in human rheumatoid arthritis. *Arthritis Rheum*; 60: 686-697.
  - **Minor M., Stenstorm G.A., Klepper S.E. Hurley M. et al. (2003):** Work group recommendations: 2002 excersise and physical activity conference; St Lours, Missouri *Arthritis Rheum*; 49: 453-4.
  - **Molenaar E.T., Voskuyl A.E., Dinant H.J., Bezemer P.D., Bores M. and Dijkmans B.A. (2004):** Progression of radiologic damage an patients with rheumatoid arthritis in clinical remission. *Arthritis Rheum*; 50: 36-42.
  - **Montesinos M.C. et al. (2007):** The anti-inflammatory mechanism of methotrexate dependson extracellular conversion of adenine nucleotides to adenosine by ecto-5-nucleotidase: finding in a study of ecto-5-nucleotidase gene deficient mice. *Arthritis Rheum*; 56: 1440-1445.




- 
- **Mori M., Yamada R., Kobayashi K., Kawaida R. and Yamamoto K. (2005):** Ethnic differences in allele frequency of auto immune. Disease associated SNPS. *J Hum Genet*; 50: 264-266.
  - **Moss M.L., Sklair-Tavron L. and Nudelman R. (2008):** Drug insight: tumour necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. *Nat Clin Pract Rheumatol*; 4: 300-9.
  - **Nakano K.K. (1995):** Neurological complications of rheumatoid arthritis. *Orthop. Clin. North Am*; 8: 712.
  - **Nam J.L., Winthrop K.L., Van Vollenhoven R.F. et al. (2010):** Current evidence for the management of rheumatoid with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA, *Ann Rheum Dis*, 69: 976-86.
  - **Naredo E., Moller I., Moragues C. et al. (2006):** EULAR working group for musculoskeletal ultrasonography, interobserver reliability in musculoskeletal ultrasonography: results from a "teach the teachers" rheumatologist course. *Ann Rheum Dis*, 65: 14-19.
  - **Neogi T., Aletaha D., Silman A.J. et al. (2010):** The American college of rheumatology/European league against rheumatism classification criteria for rheumatoid arthritis: phase 2 methodological report. *Arthritis rheum*; 62: 2582-91.




- 
- **Nicola P.J., Maradit-Kremers H., Roger V.L. et al. (2005):** The risk of congestive heart failure in rheumatoid arthritis: A population based study over 46 years. *Arthritis Rheum*; 52(2): 412-420.
  - **Nielen M.M., Vander Hoist A.R., Van Schaardenburg D. et al. (2005):** Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. *Ann Rheum Dis*; 64: 1199-204.
  - **Nikolaisen C., Figenschau Y. and Nossent J.C. (2008):** Anaemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect disease course or mortality. *J Rheumatol*; 35: 380-6.
  - **Nishimura K., Sugiyama D., Kogata Y. et al. (2007):** Meta-analysis: diagnostic accuracy of anticyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. *Ann. Intern-Med.* 146(11): 797-808.
  - **Noss E.H. and Brenner M.B. (2008):** The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. *Immunol Rev*, 223: 252-270.
  - **O'Dell J.R. et al. (2002):** Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*; 46: 1164-1170.




- 
- **O'Dell J.R. et al. (1996):** Treatment of rheumatoid arthritis with methotrexate alone, sulfa salazine and hydroxychloroquine, or a combination of all three medications. *N. Engl. J. Med.* 334; 1287-1291.
  - **Osoba D. (2007):** Translating the science of patient reported outcomes assessment into clinical practice. *J Natl Cancer Inst Monogr*; 37: 5-11.
  - **Ostergaard M., Pedersen S.J. and Dohn U.M. (2008):** Imaging in rheumatoid arthritis-status and recent advances for magnetic resonance imaging, ultrasonography, computerized tomography and conventional radiography. *Best Pract Res Clin Rheumatol*; 22(6): 1019-44.
  - **Osterhaus J.T., Purcaru O., Richard L. (2009):** discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific work productivity survey (WPS-RA), *Arthritis Res Ther*, 11: R73.
  - **Paniagua R.T., Sharpe O., Ho P.P., Chan S.M., Chang A., Higgins I.P. et al. (2006):** Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. *J Clin Invest*; 116: 2633-2642.
  - **Papazoglou D., Augello G., Tagliaferri M. et al. (2006):** Evaluation of a multisensor arm band. In estimating energy expenditure in obese individuals. *Obesity (Silver Spring)*; 14: 2217-2223.
  - **Paulus H. (1996):** Monitoring radiographic changes in early: rheumatoid arthritis. *J. Rheumatol*; 23: 801-805.




- 
- ***Pedersen M., Jacobsen S., Garred P., Madsen H.O., Karlund M., Svejgaard a. et al. (2007):*** Strong combined gene-environment effect in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in denmark . *Arthritis Rheum*; 56(5): 1446-53.
  - ***Pincus T., Summey J.A., Soraci S.A. et al. (1983):*** assessment of patient satisfaction in activities of daily living using a modified stanford health assessment questionnaire. *Arthritis Rheum*, 26: 1346-53.
  - ***Plach S.K., Heidrich S.M., Waite R.M. (2003):*** Relationship of social role quality to psychological well-being in women with rheumatoid arthritis.
  - ***Plenge R.M. and Criswell L.A. (2008):*** Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: Current challenges and future directions. *Curr Opin Rheumatol*; 20: 145-152.
  - ***Plenge R.M., Cotsapas C., Davies L., Price A.L., de Bakker P.L., Maller J., Pe'er I. et al. (2007):*** Two independent alleles at 6q23 associated risk of rheumatoid arthritis.
  - ***Power M., Harper A. and Bullinger M. (1999):*** The World Health Organization. WHOQOL-100: tests of the universality of quality of life in 15 different cultural group worldwide *Health Psychol*; 18: 495-505.
  - ***Raychaudhuri S., Remmers E.F., Lee A.T., Hackett R., Guiducci C., Burt N.P. et al. (2008):*** Common variants at CD40 and other IOCI confer risk of rheumatoid arthritis. *Nat Genet*; 40: 1216-1223.




- 
- **Reilly M.C., Gooch K.L., Wong R.L. et al. (2010):** Validity, reliability and responsiveness of the work productivity and activity impairment questionnaire. *Rheumatology (Oxford)*, 49: 812-819.
  - **Reilly M.C., Zbrozek A.S. and Dukes E.M. (1993):** The validity and reproductibility of a work productivity and activity impairment instrument. *Pharmacoeconomics*, 4: 353-365.
  - **Remmers E.F., Plenge R.M., Lee A.T., Graham R.R., Hom G., Behrens T.W., de Bakker P.I., Le J.M. et al. (2007):** STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. *N Engl J Med*; 357: 977-986.
  - **Rnssak S., Croft J. Jr., Frust D. et al. (2003):** The use of rheumatoid arthritis health related quality of life patient questionnaire in clinical practice: lessons learned. *Arthritis Rheum*; 49: 574-584.
  - **Roubenoff R. (2009):** Rheumatoid cachexia: a complication of rheumatoid arthritis moves into 21 century. *Arthritis Res Ther*, 11: 108.
  - **Russak S.M., Sherboure C.D., Lubeck D.P., Palus H.D. et al. (2003):** Validation of a rheumatoid arthritis health related quality of life instrument. *The CSHQ-AR arthritis Rheum*; 49: 798-803.
  - **Russell L.B., Siegel J.E., Daniels N., gold M.R. Luce B. et al. (1996):** Cost effectiveness analysis as guide to resource allocation in health: roles and limitations. In: Gold MR., Siegel JE, Russell LB, eds. *Cost-effectiveness in health and medicine*. Oxford, England: Oxford University Press; 3-24.




- 
- **Rutkauskaitė E., Volkmer D., Shigeyama Y., Schedel J., Pap G., Müller-Lander U. et al. (2005):** Retroviral gene transfer of antisense construct against membrane type 1 matrix metalloproteinase reduce the invasiveness of rheumatoid arthritis synovial fibroblasts. *Rthritis Rheum*; 52: 2010-2014.
  - **Sacks J.J., Helmick C.G. and Langmaid G. (2004):** Death from arthritis and other rheumatic conditions, united states. *J Rheumatol*; 31: 1823-1828.
  - **Salaffi F., De Angelis and Grassi W. (2005):** On behalf of the marche pain prevalence investigation group (MAPPING) study: prevalence of musculoskeletal conditions in an Italian population sample. Results of a regional community-based study. *The MAPPING study Clin Exp Rheumatol*, 23: 819-28.
  - **Saroux A., Berthelot J.M., Chales G. et al. (2001):** Ability of the American college of Rheumatology 1987. Criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. *Arthritis Rheum* 44: 2485-2491.
  - **Scheier M.F., Wrosh C., Baum A., Cohen S. et al. (2006):** The life Engagement test: assessing purpose in life; *J Beav Med*; 29: 291-298.
  - **Schett G. (2007):** Erosive arthritis. *Arthritis Rest her*; 9(Suppl 1): S2.
  - **Schiepers O.J., Wichers M.C. and Maes M. (2005):** Cytokines and major depression. *Prog Neuropsychopharmacol Biol Psychiatry*, 29(2): 201-17.




- 
- **Schiff M. et al. (2008):** Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase II, multi-centre, randomized, double blind, placebo-controlled study in patients with rheumatoid arthritis and inadequate response to methotrexate. *Ann Rheum Dis*; 67: 1096-1103.
  - **Schleicher H., Alonso C., Shircloff E.A., Muller D. et al. (2005):** In the face of pain: the relationship between psychological well being and disability in women with fibromyalgia. *Psychosom*, 74: 231-239.
  - **Schochat T., Pilz C. and Neurmer R. (2003):** The indicators of rehab status questionnaire version 3 (IRES-3) in 1818 rehabilites with musculoskeletal disease. *Rehabilitation (Stuttg)*; 42: 236-44.
  - **Schur P.H. (2005):** Anti-cyclic citrullination peptide antibodies: diagnostic, predictive and monitoring value in RA. *Int J Adv Rheumatol*; 3: 77-83.
  - **Scott D.L., Smith C. and Kingsley G. (2005):** What are the consequences of early rheumatoid arthritis for the individual? *Best Pract Res Clin Rheumatol*, 19: 117-36.
  - **Sebbag M., Moinard N., Auger I. et al. (2006):** Epitopes of human fibrin recognized by the rheumatoid arthritis-specific antibodies to citrullinated proteins. *Eur J Immunol*; 36: 2250-63.
  - **Shaw J.W., Johnson J.A. and Coons S.J. (2005):** US evaluation of the EQ-5D health states. Development and testing of the D1 valuation model. *Med Care*; 43: 203-220.




- 
- **Sheehy C., Murphy E. and Barry M. (2006):** Depression in rheumatoid patients underscoring the problem. *Rheumatology*, 45(11): 1325-7.
  - **Silman A.J., Hawker G.A. and Aletaha D. (2009):** ACR/ACHP Annual specific meeting arthritis and rheumatism, volume 60: 16-21.
  - **Sinjders G.F., den Broeder A.A., Bevers K. et al. (2008):** Measurement characteristics of a new rapid anti-CCP2 test compared to the anti-CCP2 ELTSA. *Scand J Rheumatol*; 151-4.
  - **Skevington S.M., Lofty M., O'Connell KA. (2004):** For the WHOQOL group. The world Health Organization WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. *Res*; 13: 299-310.
  - **Smolen I.S., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J. et al. (2008):** Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo. Controlled randomized trial. *Lancet*; 371: 987-97.
  - **Smolen I.S., Van der Heijde D.M., Stclair E.W., Emery P., Bathon J.M. et al. (2006):** For the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset (ASPIRE) study group. Predictors of joint damage in patients with early RA treated with high-dose methotrexate with or without concomitant infliximab: results from ASPIRE trial. *Arthritis Rheum*; 54: 702-10.




- 
- **Smolen J.S., Han C., Van der Heijde D.M., Emery P., Bathan J.M., Keystone E. et al. (2009):** Radiographic changes in RA patients attaining different disease activity state with methotrexate monotherapy and infliximals blockade. *Ann Rheum Dis*; 88: 823-7.
  - **Smolen J.S., Landewé R., Breedveld F.C. et al., (2010):** EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti rheumatic drugs. *Ann Rheum Dis*, 69: 964-75.
  - **Snir O., Widhe M., Von Spee C., Lindberg J., Padyukov L., Lundberg K. et al. (2009):** Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. *Ann Rheum Dis*; 68(5): 736-43.
  - **Sodergren A., Stegmayr B., Lundberg V., Ohman M.L. and Wallberg-Jonsson S. (2007):** Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. *Ann Rheum Dis* Feb; 66(2): 263-266.
  - **Soderlin M.K., Kautiainen H., Skogh T. and Leirisalo-Pepo M. (2004):** Quality of life and economic burden of illness in very early arthritis. A population based study in southern Sweden. *J Rheumatol*, 31(9): 1717-1722.
  - **Sokka T., Heltland M.L., Makien H., Kautiainen H., Horselva Petersen K. et al. (2008):** For the questionnaire in standard monitoring of patients with rheumatoid arthritis group. Remission and rheumatoid: data on patients receiving usual care in twenty. Four countries. *Arthritis Rheum*; 58: 2642-51.




- 
- **Sokka T., Kautiaanonm H., Hannonen P. and Pincus T. (2006):** Changes in health assessment questionnaire disability scores over five years in patient with rheumatoid arthritis compared with general population. *Arthritis Rheum*; 45 : 34-38.
  - **Sokka T., Krishnan E., Hakkinen A. and Hannonen P. (2003):** Functional disability in rheumatoid arthritis patients compared with a community population in Finland. *Arthritis Rheum*; 48: 59-63.
  - **Solomon D.H., Goodson N.J., Katz J.N. et al. (2006):** Patterns of cardiovascular risk in rheumatoid arthritis. *Ann Rheum Dis*; 65(12): 1608-1612.
  - **Soo's L., Szekanecz Z., Szabo Z. et al. (2007):** Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. *J Rheumatol*; 34: 1658-63.
  - **Soubrier M., Pnéchal X., Sibilia J. et al. (2009):** Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. *Rheumatology (Oxford)*, 48: 1429-34.
  - **Stamm T.A., Aletaha D., Pflugbeil S., Kapral T., Montag K., Machold K.P. et al. (2007):** The use of data base for quality assessment in rheumatoid arthritis. *Clin Exp Rheumatol*; 25(Suppl 47): 82-5.
  - **Stamm T.A., Gieza A., Coenen M et al. (2005):** Validating the international classification of functioning, disability and health comprehensive core set for rheumatoid arthritis from the patient perspective: a qualitative study. *Arthritis Rheum*, 53: 431-439.




- 
- **Stamm T.A., Gieza A., Coenen M., Machold K.P., Nell V.P. Smolen J.S. et al. (2007):** Validating the international classification of functioning. Disability and health comprehensive core set for rheumatoid arthritis from the patient perspective: a qualitative study. *Arthritis Rheum*; 53: 431-9.
  - **Strand V. and Crawford B. (2005):** Improvement in health related quality of life in patients with SLE following sustained reduction in anti-dsDNA antibodies. *Expert Rev Pharmacoeconomics outcomes Res*; 5: 317-326.
  - **Stucki G., Gieza A., Geyh S. et al. (2004):** ICF care sets for rheumatoid arthritis. *J Rehabil Med*, 44(Suppl): 87-93.
  - **Summers G.D., Metsios G.S., Stavropoulos-Kalinoglou A. et al. (2010):** Rheumatoid cachexia and cardiovascular disease. *Nat Rev Rheumatol*; 6: 445-451.
  - **Suzaki A., Yamada R. and Yamamoto K. (2007):** Citrullination by peptidylarginine deiminase in rheumatoid arthritis. *Ann NY Acad Sci*; 1108: 323-339.
  - **Svensson B. et al. (2005):** Low-dose prednisolone in addition to the initial disease modifying anti rheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increase the remission rate: a two-year randomized trial. *Arthritis Rheum*; 52; 3360-3370.
  - **Swezey R.L. (1993):** Rehabilitation medicine and arthritis in mc carty D.J., Koopman WJ (eds): *Arthritis and Allied Conditions*, 12<sup>th</sup> ed, Philadelphia, Lea and Febiger; 887-917.




- 
- **Symmons D.P. (2007):** Classification criteria for rheumatoid arthritis: time to abandon rheumatoid factor? *Rheumatology*; 46: 725-726.
  - **Szekanecz Z., Soos L., Szabo Z., Fekete A., Kapitany A., Vegvari A. et al. (2008):** Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets? *Clin Rev Allergy Immunol*; 34(1): 26-31.
  - **Takizawa Y., Suzuki A., Sawada T., Ohsaka M., Inoue T., Yamada R. et al. (2006):** Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids. *Ann Rheum Dis*; 65(8): 1013-20.
  - **Tanimoto K. (1993):** Diagnostic criteria for rheumatoid arthritis and their evaluation, 33(1): 95-100.
  - **Thomson W., Baton A., K X., Eyre S., Hinks A., Bowes J., Donn R. et al. (2007):** Rheumatoid arthritis association at 6q23. *Nat Genet*, 39: 1431-1433.
  - **Treharne G.J., Lyons A.C., Booth D.A., Kitas G.D. (2007):** Psychological well being across 1 year with rheumatoid arthritis: coping resources as buffers of perceived stress. *Br. J. Health Psychol* 12: 323-345.
  - **Treharne G.J., Lyons A.C., Booth D.A. and Kitas G.D. (2007):** Psychological well-being across 7 years with rheumatoid arthritis: coping resources as buffers of perceived stress. *Br J health Psychol*; 12: 323-345.
  - **Tsevast J., Weeks J.C., Guadagnoli E. et al. (1994):** Using health-related quality of life information: clinical encounters, clinical trials, and health policy. *J Gen Intern Med*; 9: 576-582.




- 
- **Tsevat J. (2000):** What do utilizes measure? *Med. Care*; 38 (Supl): 11160-11164.
  - **Turesson C. and Jacobsson L.T.H. (2004):** Epidemiology of extra-articular manifestations in rheumatoid arthritis *Scan J Rheumatol*; 33: 65-72.
  - **Uhlig T., Loge J.H., Kristiansen I.S. et al. (2007):** Quantification the general population. *J Rheumatol*, 34: 1241-7.
  - **Van Den Ende C.H., Vliet Vlielond T.P., Munneke M. and Hazes J.M. (2008):** Withdrawn Dynamic exercise therapy for treating rheumatoid arthritis, *Cochrane Database Syst Rev*, 1: 00322.
  - **Van der Heijde D., Kalden J., Scott D., Smolen J. and Strand V. (2004):** Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years. *Ann Rheum Dis*; 63: 737-739.
  - **Van der Heijde D., Klareskog L., Landewe R., Bruyn G.A., Cantagrel A., Durez P. et al. (2007):** For the TEMPO study investigators. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. *Arthritis Rhaum*; 56: 3928-39.
  - **Van der Helm-Van Mil A.H., Verpoort K.N., Le Cessie S., Husizinga T.W., de Vries R.R. and Toes R.E. (2007):** The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. *Arthritis Rheum*; 56(2): 425-32.




- 
- **Van der Helm-Van Mil A.H., Verport K.N., Breedveld F.C., Huizinga T.W., Toes R.E. and de Vries R.R. (2006):** The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrillinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. *Arthritis Rheum*; 54: 1117-1121.
  - **Van der Zee K.I., Sanderman R., Heyink J. (1996):** A comparison of two multidimensional measures of health status: the Nottingham health Profile and the RAND-36-Item Survey 1.0. *Qual Life Res*, 5: 165-174.
  - **Van Oene M., Wintle R.F., Liu X., Yazdanpanah M., Gu X., Newman B. et al. (2005):** Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not crohn's disease, in candadian populations. *Arthritis Rheum*; 52: 1993-1998.
  - **Van Tayl L.H., Vlad S.C., Felson D., Wells C. and Bores M. (2009):** Defining remission in rheumatoid arthritis: results of an Initial American College of Rheumatology/European league against rheumatism consensus conference. *Arthritis Rheum*; 61: 704-10.
  - **Van Venrooij W.J. and Pruijn G.J. (2000):** Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. *Arthritis Res*; 2: 249-51.
  - **Van Venrooij W.J., Zendman A.J. and Pruijn G.J. (2006):** Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. *Auto Immune Rev*; 6: 37-41.




- 
- ***Vandecreek L., Paget S., Horton R., Robbins L. et al. (2004):*** Religions and non-religions coping methods among persons with rheumatoid arthritis. *Arthritis Rheum*, 51: 49-55.
  - ***Vander Gruyssen B., Cantaert T., Nogueira L. et al. (2006):*** Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays. *Arthritis Res Ther*; 8: R122.
  - ***Veale D.J. and Fearon U. (2006):*** Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting. *Best Pract Res Clin Rheumatol*; 20: 941-947.
  - ***Visser K. and Van Der Heijde D. (2008):*** Optimal doage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. *Ann Rheum Dis*; 359: 1173-7.
  - ***Voscenaar E.R., Despres N., Lapointe E. et al. (2004):*** Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. *Arthritis Res Ther*; 6: R142-50.
  - ***Waheed A., Hameed K., Khan A.M. et al. (2006):*** The burden of anxiety and depression among patients with chronic rheumatologic disorders at a tertiary care hospital clinic in Karachi, Pakistan. *J Pak Med Assoc*, 56(5): 243-7.
  - ***Ware J.E. and Dewey J. (2000):*** Health status and outcome assessment tools. *Int Electronic J Health Education*; 3: 138-148.
  - ***Ware J.E. and Sherbourne C.D. (1992):*** The MOS-36-item short-form health. Survey (SF-36). I conceptual framework and item selection. *Med. Care*; 30: 473-483.



- 
- **Weaver C.T., Harrington L.E. and Managan P.R. (2006):** Th17: an effector CD4 T cells lineage with regulatory T cell ties. *Immunity*; 24: 677-688.
  - **Weinblatt M. et al. (2003):** Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trail. *Arthritis Rheum*; 48: 35-45.
  - **Weinblatt M.E. et al. (1999):** Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. *Arthritis Rheum*; 42: 1322-1328.
  - **Weisman M.H., Paulus H.D., Russak S.M., Lubeck D.P. et al. (2003):** Development of a new instrument for rheumatoid arthritis: the Cedars-Sinai-Health-Related Quality of life instrument (CSHQ-RA). *Arthritis Rheum*; 49: 78-84.
  - **Wesoly J., Van der helm-Van Mil A.H., Toes R.E., Chokkalingam A.P., Carlton V.E. et al. (2005):** Association of the PTPN22 C1858T single nucleotide polymorphism with rheumatoid arthritis phenotypes in inception cohort. *Arthritis Rheum*; 52: 2948-2950.
  - **Westby M.D. and Minor (2006):** Exercise and physical activity. *Clinical care in the rheumatic diseases. 3<sup>rd</sup> edition.* Atlanta. Association of Rheumatology Health Professionals; 211-200.



- 
- **Westwood O.M., Nelsen P.N. and Hay F.C. (2006):** Rheumatoid factors: What's new? *Rheumatology (Oxford)*; 45(4): 379-85.
  - **William J.T., Myers J., Russel T.S., Kathryn M.M. and Weatherall M. (2004):** Arthritis and rheumatism. *American college of Rheumatology*, 51: 350-557.
  - **Willkens R.F., Sharp J.T., Stablein D., Marks C. and wortmann R. (1995):** Comparison of azathioprine, methotrexate and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment. *Arthritis Rheum*; 38: 1799-1806.
  - **Winchester R.J., Koffler D., Litwin S.D. et al. (1991):** Observation on the esivaphilia of certain patients with rheumatoid arthritis. *Arthritis Rheum*; 14: 650-665.
  - **Wu J., Katrekar A., Honigberg L.A., Smith A.M., Gonn M.T., Tang J., Jeffery D., Mortara K. et al. (2006):** Identification of substrates of human protein-tyrosine phosphatase PTPN22. *J Biol Chem*; 281: 11002-11010.
  - **Yamada H., Nakashima Y., Okazaki K. et al. (2008):** Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. *Annals of Rheumatic Diseases*; 67: 1299-1304.
  - **Yamada R. and Yamamoto K. (2007):** Mechanism of diseases: genetic of rheumatoid arthritis: ethnic differences an disease associated genes. *Nat Clin Pract Rheumatol*, 3: 644-650.



- 
- **Young A., Koduri G. et al. (2007):** Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. *Rheumatology (Oxford)*; 46: 350-7.
  - **Zhang W., Bansback N., Guh D., Li X. et al. (2008):** Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. *J Rheumatol*, 35: 1729-1736.
  - **Ziff M. and Baum I. (1993):** Laboratory finding in rheumatoid arthritis. In “Arthritis and allied conditions” Ed by Hollander J and Philadelphia. 367.
  - **Zrour S.H., Touzi M., Bejia J., Golli M., Routabi N. et al. (2005):** Correlations between high-resolution computed tomography of the chest and clinical function in patients with rheumatoid arthritis: prospective study in 75 patients. *Joint Bone Spine*, 72: 41-47.